HPTN 083: Injectable Cabotegravir vs Oral TDF/FTC for HIV PrEP in MSM and TGW

Phase 3, randomised, double-blind trial of cabotegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 at week 153 and Number of Participants Experiencing Grade 2 or Higher Clinical and Laboratory Adverse Events at week 153. Started Dec 2016; status: completed.